During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent t...During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.展开更多
肺癌严重威胁人们的生命健康,在中国,肺癌预计在未来几十年内都呈增长态势,动态增强磁共振(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)的各种动力学参数、曲线能间接反映肿瘤血供和肿瘤血管表面渗透性,在指导肺癌...肺癌严重威胁人们的生命健康,在中国,肺癌预计在未来几十年内都呈增长态势,动态增强磁共振(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)的各种动力学参数、曲线能间接反映肿瘤血供和肿瘤血管表面渗透性,在指导肺癌个体化治疗,评价疗效方面有独特优势,本文对动态增强磁共振在非小细胞肺癌疗效评估中的应用和进展进行综述。展开更多
文摘During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.
文摘肺癌严重威胁人们的生命健康,在中国,肺癌预计在未来几十年内都呈增长态势,动态增强磁共振(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)的各种动力学参数、曲线能间接反映肿瘤血供和肿瘤血管表面渗透性,在指导肺癌个体化治疗,评价疗效方面有独特优势,本文对动态增强磁共振在非小细胞肺癌疗效评估中的应用和进展进行综述。
